MiNK Therapeutics presented preclinical data demonstrating its off-the-shelf iNKT cell therapies, agenT-797 and MiNK-215, effectively target tumor resistance mechanisms and senescent cells in cancer models. AgenT-797 reprogrammed immune-suppressive environments in colorectal cancer liver metastases to enhance tumor-cell killing when combined with checkpoint inhibitors. MiNK-215, engineered to target fibroblast activation protein, cleared senescent tumor cells and fibroblasts, addressing persistent inflammation and tissue remodeling. These findings support ongoing Phase 2 trials in colorectal cancer and acute respiratory failure, highlighting the therapies' potential across cancer and inflammatory diseases.
MiNK Therapeutics' new data on iNKT cell therapies comes as 94 of 150 priced Health-sector US stocks on Pluang fell today. For readers following health stocks, here is Pluang's market snapshot as of Nov 06, 2026 20:42 WIB: ERAS (Erasca Inc.) rose 3.77% to USD 13.77 with a typical hold time of 4 days; TXG (10X Genomics Inc.) dropped 3.65% to USD 55.94, with Pluang order activity showing 88% sell and 12% buy; HRTX (Heron Therapeutics Inc.) gained 3.54% to USD 0.29, with 76% buy orders and a typical hold time of 38 days.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
